THE AMERICAN COLLEGE OF CARDIOLOGY’S IC3 (IMPROVING CONTINUOUS CARDIAC CARE) PROGRAM AND HEART FAILURE PERFORMANCE MEASURES: A REPORT OF THE FIRST 14,000+ PATIENTS  by Chan, Paul et al.
A139.E1303
JACC March 9, 2010
Volume 55, issue 10A
 QUALITY OF CARE AND OUTCOMES ASSESSMENT 
THE AMERICAN COLLEGE OF CARDIOLOGY’S IC3 (IMPROVING CONTINUOUS CARDIAC CARE) 
PROGRAM AND HEART FAILURE PERFORMANCE MEASURES: A REPORT OF THE FIRST 14,000+ 
PATIENTS
ACC Poster Contributions
Georgia World Congress Center, Hall B5
Monday, March 15, 2010, 3:30 p.m.-4:30 p.m.
Session Title: Safety
Abstract Category: Quality of Care
Presentation Number: 1192-157
Authors: Paul Chan, Donna Buchanan, Fran F. Fiocchi, Fengming Tang, Kristi Mitchell, Duane Thrutchley, William J. Oetgen, John S. Rumsfeld, John A. 
Spertus, Mid America Heart Institute, Kansas City, MO, The American College of Cardiology, Washington DC, DC
Background: While the inpatient management of heart failure (HF) has been described by hospital registries, little is known about the care of 
outpatients with HF. We examined the first 14,000+ outpatients enrolled into the American College of Cardiology’s IC3 (Improving Continuous Cardiac 
Care) Program to provide initial insights into the quality of outpatient care in HF.
Methods: IC3 is the first national, prospective office-based quality improvement program of cardiac patients designed to capture and report 
outpatient performance measures (PM) and provide decision support tools to optimize the quality of care delivered to these patients. We examined 
the proportion of HF patients whose care was compliant with established American College of Cardiology and American Heart Association PMs. 
Patients were individually evaluated for each PM and could be excluded for one, but retained in others.
Results: There were 14,464 unique patients enrolled from 20 U.S. practices, which accounted for 18,021 clinical visits. Of these, 5012 (34.7%) 
had HF, and 1076 (21.5%) of those with HF had a left ventricular ejection fraction [LVEF] <40%. Data from IC3 were feasibly collected for all 11 
HF PMs to allow for assessments of adherence. Adherence to the HF PMs ranged from being very high for blood pressure (96.7% [6251/6462 
encounters]) and weight (96.0% [6149/6402 encounters]) assessment and for beta-blocker therapy in patients with LVEF <40% (93.1% 
[981/1054]), to very poor for HF patient education (43.8% [2194/5012]) and assessment of HF clinical signs on exam (23.7% [1533/6462]). 
Adherence to ACE inhibitor or ARB in patients with LVEF <40% (85.8% [879/1025]), warfarin for patients with concurrent atrial fibrillation (80.6% 
[859/1066]), and clinical symptom assessment (88.9% [5742/6462]) fell between these extremes.
Conclusions: From this first 14,000+ patient experience in the outpatient IC3 Program, we found that 1 in 3 patients had HF, fewer than 1 in 4 HF 
patients had a systolic etiology to their HF, and all the PMs could be reliably assessed. Adherence to the HF PMs was variable, even after accounting 
for exclusion criteria, suggesting substantial opportunity for improving the quality of outpatient care.
